Skip to main navigation
Skip to main content
ANI Pharmaceuticals Logo
  • About
    • Executive Team
    • Board of Directors
    • How We Operate
      Quality Capabilities
    • Locations
    • News
  • Products
  • Contract Manufacturing
  • Investors
  • Careers
    • Careers
    • Benefits
    • Available Positions
    • Application
  • Contact
    • Contact Us
    • Locations

News

  • Overview
    • News
    • Events & Presentations
    • Stock Information
      • Stock Quote & Chart
      • Investment Calculator
      • Analyst Coverage
    • Financials
      • Quarterly Results
      • Annual Reports
      • SEC Filings
    • Governance
      • Governance Documents
      • Executive Management
      • Board of Directors
      • Committee Composition
    • Resources
      • Investor FAQs
      • Information Request Form
      • Investor Email Alerts
      • Investor Contacts
Site Search
08/03/2022
ANI Pharmaceuticals Announces the Launch of Acebutolol Hydrochloride Capsules USP
07/28/2022
ANI Pharmaceuticals Acquires ANDAs from Oakrum Pharma, LLC
07/25/2022
ANI Pharmaceuticals to Discuss Second Quarter 2022 Financial Results on August 8, 2022, at 8:00 a.m. ET
07/18/2022
ANI Pharmaceuticals Appoints Meredith W. Cook as SVP, General Counsel and Corporate Secretary
06/22/2022
ANI Pharmaceuticals Announces FDA Approval and Imminent Launch of Clorazepate Dipotassium Tablets USP
06/21/2022
ANI Pharmaceuticals Adopts Veeva Commercial Cloud to Better Support Rare Disease Patients
06/02/2022
ANI Pharmaceuticals Announces Consolidation of Manufacturing Network, Capturing Operational Synergies Post Novitium Acquisition
06/01/2022
ANI Pharmaceuticals Announces the FDA Approval and Imminent Launch of Fludrocortisone Acetate Tablets USP
05/20/2022
ANI Pharmaceuticals to Present at Upcoming Healthcare Investor Conferences
05/10/2022
ANI Pharmaceuticals Reports First Quarter 2022 Results; Provides Purified Cortrophin® Gel Net Revenue Guidance and Full-Year 2022 Total Company Net Revenue Guidance of $295 Million to $315 Million

Pagination

  • Current page 1
  • Page 2
  • Next page next ›
  • Last page last »
Displaying 1 - 10 of 18

Contact Us

INVESTOR CONTACT

In-Site Communications, Inc.
Lisa M. Wilson

212-452-2793
IR@anipharmaceuticals.com

Quick Links

  • SEC Filings
  • Investor FAQs
  • Information Request Form

Investor Email Alerts

*
Unsubscribe
ANI Pharmaceuticals Logo
  • Products
  • Investors
  • Careers
  • Contact Us
  • Privacy Policy
  • Terms of Use
  • Accessibility
© Copyright 2022 ANI Pharmaceuticals, Inc.
  • follow us on linkedin
  • follow us on youtube